-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple sclerosis (MS) is characterized by muscle weakness and increased paralysis, and a variety of therapies can help slow the progression of the disease at an early stage, but it is difficult to reverse the damage that has occurred in neuronsA new study in PNAS suggests that bear palicacid, a compound found in fruits such as apples and plums, and some herbs can reduce further damage to neurons and help rebuild the protective palate that covers neurons, thus reversing the damageresearchers experimented using laboratory-grade sascoic acid purified, using an established mouse model of multiple sclerosis, EAE, that mimics human disease, slowly developing disease during its life, and that around the 12th day, when signs of MS, partial paralysis, and the most effective drugs currently available, the mice begin the acute phase of the diseaseresearchers began treating mice at the end of the 60th day, when the brain and spinal cord developed chronic tissue damage that needed to be repaired and regeneratedOn the 20th day of treatment, the paralysed mice recovered to walk after treatment, albeit weakThe researchers say that while this is not a cure, if a similar response is seen in humans, it will represent a significant change in quality of lifeAnd most importantly, it's a reversal that's never seen at such a late stagebear palaenic acid therapy can alleviate chronic EAE, promote myelin regeneration and reduce axial mutation and neuronal dendritic damage
in addition, the researchers also studied how bear palaeontine acid acts on cells, and they observed that it inhibits Th17 cells, an immune cell that is one of the main drivers of MS's pathological autoimmune responseMany therapies now seem to inhibit Th17, but the compound activates precursor cells and matures them into much-needed myelin-producing cells, i.efewer glial cellsThis maturation is the most critical, MS in the manufacture of myelin less protrusive glial cells exhausted, and the production of new less protoscoction cells stem cells in a dormant state, unable to matureThe compound helps activate these stem cells and may be the cause of the reversal of symptomsthe eAE immunomodulation and neuroregeneration models mediated by bear fruit acidit is encouraging to see in the laboratory that a compound can both stop and repair damage from multiple diseases, although the evidence from animal disease models is preliminaryThe next step for researchers to test the safety of compounds, which still has many tests to complete before the first clinical trial, is a great precursor to the treatment of disease